Clinical trial
Evaluation of Galantamine in the Treatment of Alzheimer's Disease
NCT00000172 · Janssen, LP, Industry · Completed
Key facts
| NCT number | NCT00000172 |
|---|---|
| Title | Evaluation of Galantamine in the Treatment of Alzheimer's Disease |
| Official title | Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen |
| Lead sponsor | Janssen, LP, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Galantamine |
| First posted | Nov 1, 1999 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: